Perforating folliculitis in a patient treated with nilotinib: A further evidence of C-kit involvement

American Journal of Dermatopathology

Volumn 36, Issue 7, 2014, Pages 592-593

  Llamas Velasco, Mar ^a   Steegmann, Juan Luis ^b   Carrascosa, Raquel ^b   Fraga, Javier ^b   García Diez, Amaro ^b   Requena, Luis ^c  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c Departments of Dermatology Hospital Universitario de la Princesa ^*  (Spain)

Author keywords

drug eruptions; folliculitis; hair follicle; nilotinib

Indexed keywords

DASATINIB; EMOLLIENT AGENT; KERATIN; LIVER ENZYME; NILOTINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SORAFENIB; STEM CELL FACTOR; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; ARTICLE; BASOPHIL; BIOPSY; CASE REPORT; CELL DEATH; CHRONIC MYELOID LEUKEMIA; DRUG INDUCED DISEASE; EPIDERMIS HYPERPLASIA; FOLLICULITIS; FOLLOW UP; HAIR FOLLICLE; HUMAN; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; PAPULE; PARAKERATOSIS; PERFORATING FOLLICULITIS; PRIORITY JOURNAL; PRURITUS; RASH; CHEMICALLY INDUCED; DRUG ERUPTIONS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; DRUG ERUPTIONS; FOLLICULITIS; HAIR FOLLICLE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; THIAZOLES;

EID: 84903301414     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0b013e31828cf3b7     Document Type: Article

References (11)

1. Wolber C, Udvardi A, Tatzreiter G, et al. Perforating folliculitis, angioedema, hand-foot syndrome-multiple cutaneous side effects in a patient treated with sorafenib. J Dtsch Dermatol Ges. 2009;7: 449-452.
2. Arin MJ, Kurschat P, Mahrle G. Primary perforating granulomatous folliculitis-scarring deep type. Eur J Dermatol. 2010;20: 364-366.
3. Gilaberte Y, Coscojuela C, Vazquez C, et al. Perforating folliculitis associated with tumour necrosis factor-alpha inhibitors administered for rheumatoid arthritis. Br J Dermatol. 2007;156: 368-371.
4. Minami-Hori M, Ishida-Yamamoto A, Komatsu S, et al. Transient perforating folliculitis induced by sorafenib. J Dermatol. 2010;37: 833-834.
5. Saray Y, Seckin D, Bilezikci B. Acquired perforating dermatosis: clinicopathological features in twenty-two cases. J Eur Acad Dermatol Venereol. 2006;20: 679-688.
6. Hahn O, Stadler W. Sorafenib. Curr Opin Oncol. 2006;18: 615-621.
7. Paz C, Querfeld C, Shea CR. Sorafenib-induced eruption resembling pityriasis rubra pilaris. J Am Acad Dermatol. 2011;65: 452-453.
8. Weger N, Schlake T. Igf-I signalling controls the hair growth cycle and the differentiation of hair shafts. J Invest Dermatol. 2005;125: 873-882.
9. Karlsson L, Bondjers C, Betsholtz C. Roles for PDGF-A and sonic hedgehog in development of mesenchymal components of the hair follicle. Development. 1999;126: 2611-2621.
10. Kamp H, Geilen CC, Sommer C, et al. Regulation of PDGF and PDGF receptor in cultured dermal papilla cells and follicular keratinocytes of the human hair follicle. Exp Dermatol. 2003;12: 662-672.
11. Kossard S, Scurry J, Killingsworth M. Necrotizing infundibular crystalline folliculitis. Br J Dermatol. 2001;145: 165-168.